Clinical case of joint usage of inotropic and vasodilating drugs in acute decompensated heart failure

Vlasov P.N.; Geyze A.V.

doi:https://doi.org/10.17116/kardio2017101234-38

Vlasov P.N.

Clinical hospital of emergency medicine of Krasnoyarsk named after N.S. Krapovich

Geyze A.V.

Clinical hospital of emergency medicine of Krasnoyarsk named after N.S. Krapovich

Clinical case of joint usage of inotropic and vasodilating drugs in acute decompensated heart failure

Authors:

Vlasov P.N., Geyze A.V.

More about the authors

Journal: Russian Journal of Cardiology and Cardiovascular Surgery. 2017;10(1): 34‑38

DOI: 10.17116/kardio2017101234-38

Read: 1299 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Vlasov PN, Geyze AV. Clinical case of joint usage of inotropic and vasodilating drugs in acute decompensated heart failure. Russian Journal of Cardiology and Cardiovascular Surgery. 2017;10(1):34‑38. (In Russ.)
https://doi.org/10.17116/kardio2017101234-38

Подписка 2026 Кардиология и сердечно-сосудистая хирургия (Russian Journal of Cardiology and Cardiovascular Surgery)

Использование инфографики авторами научных работ

References:

National Guidelines of OSSN, RCS, RSMST for the diagnosis and treatment of chronic heart failure (4th edition). Heart failure J. 2013;7(81):1-93.
Arutyunov AG, Dragunov DO, Arutyunov GP, Rylova AK, Pashkevich DD, Viter KV. on behalf of the study group. First Open Study of Syndrome of Acute Decompensation of Heart Failure and Concomitant Diseases in Russian Federation: Independent Registry ORAKUL. Cardiology. 2015;5:12-21.
Ponikowski P, Voors AA, Anker SD, Bueno H, John GF, Cleland JGF, Andrew JS, Coats AJS, Falk V. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure/ Eur Heart J. 2016;37(27):2129-2200. doi:10.1093/eurheartj/ehw128
Pavlikova EP, Alexandria LG, Meray IA. Inotropic therapy of acute heart failure: perspective of usage for new calcium sensitizer-levosimendan. Clinical pharmacology and therapy. 2005;14(3):79-84.
Mebazaa A, Nieminen MS, Filippatos GS, Cleland JG, Salon JE, Thakkar R, Padley RJ, Huang B, Cohen-Solal A. Levosimendan vs. dobutamine: outcomes for acute heart failure patients on beta-blockers in SURVIVE. Eur J Heart Fail. 2009;11(3):304-311. doi:10.1093/eurjhf/hfn045
Dschietzig T, Bartsch C, Richter C, Laule M, Baumann G, Stangl K. Relaxin, a pregnancy hormone, is a functional endothelin-1 antagonist: attenuation of endothelin-1-mediated vasoconstriction by stimulation of endothelin type-B receptor expression via ERK-1/2 and nuclear factor-kappaB. Circ Res. 2003;92(1):32-40.
McGuane JT, Debrah JE, Sautina L, Jarajapu YP, Novak J, Rubin JP, Grant MB, Segal M, Conrad KP. Relaxin induces rapid dilation of rodent small renal and human subcutaneous arteries via PI3 kinase and nitric oxide. Endocrinology. 2011;152(7):2786-2796. doi:10.1210/en.2010-1126
Sarwar M, Samuel CS, Bathgate RA, Stewart DR, Summers RJ. Serelaxin-mediated signal transduction in human vascular cells: bell-shaped concentration-response curves reflect differential coupling to G proteins. Br J Pharmacol. 2015;172(4):1005-1019. doi:10.1111/bph.12964
Ponikowski P, Mitrovic V, Ruda M, Fernandez A, Voors AA, Vishnevsky A, Cotter G, Milo O, Laessing U, Zhang Y, Dahlke M, Zymlinski R, Metra M, et al. A randomized, double-blind, placebo-controlled, multicentre study to assess haemodynamic effects of serelaxin in patients with acute heart failure. Eur Heart J. 2014;35:431-441. doi:10.1093/eurheartj/eht459
Teerlink JR, Cotter G, Davison BA, Felder GM, Filippatos G, Greenberg BH, Ponikowski P, Unemori E, Voors AA, Adams KFJr, Dorobantuet MI, et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet. 2013;381:29-39. doi:10.1016/S0140-6736(12)61855-8
Metra M, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, Ponikowski P, Unemori E, Voors AA, Adams KFJr, Dorobantu MI, Grinfeld M. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes. JACC. 2013;61:196-206. doi. org/10.1016/j.jacc.2012.11.005
Zhirov IV, Nasonova SN, Tereshchenko SN, Uskach TM. Clinical case of usage of serelaxin in the patient with acute decompensated heart failure. Russ J Cardiol. 2016;4:83-88.
Kobalava ZD, Villevalde SV, Solov'jova AE, Merai IA. Organoprotective effects of serelaxin in patients with severe decompensated heart failure. Ration Pharmacother Cardiol. 2016;12(4):414-423. doi:org/10.20996/1819-6446-2016-12-4-414-423
Kovaleva GV, Sutygina TYu, Koroleva LYu, Mironov NN. Case report of post-MI reccurrent left ventricular failure management with Serelaxin-recombinant human relaxin-2 (Reasanz, «Novartis»). Cardiology and cardio-vascular surgery. 2015;5:92-94.
Nieminen MS, Fruhwald S, Heunks LM, Suominen PK, Gordon AC, Kivikko M, Pollesello P. Levosimendan: current data, clinical use and future development. Heart Lung Vessel. 2013;5(4):227-245.
Fomin IV, Khomkhoeva MS. Resistance to diuretics: causes, mechanisms, approach to coping. Pharmateca. 2010;12:19-23.
Metra M, Cotter G, Gheorghiade M, Dei Cas L, Voors AA. The role of the kidney in heart failure. Eur Heart J. 2012;33(17):2135-2142. doi:10.1093/eurheartj/ehs205
Hasselblad V, Gattis Stough W, Shah MR, Lokhnygina Y, O'Connor CM, Califf RM, Adams KFJr. Relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPE trial. Eur J Heart Fail. 2007t;9(10):1064-1069.
Peacock WF, Costanzo MR, De Marco T, Lopatin M, Wynne J, Mills RM, Emerman CL. Impact of intravenous loop diuretics on outcomes of patients hospitalized with acute decompensated heart failure: insights from the ADHERE registry. Cardiology. 2009;113(1):12-19. doi:10.1159/000164149
Ronco C, McCullough P, Anker SD, Anand I, Aspromonte N, Bagshaw SN, Bellomo B, Berl T, Bobek I, Cruz DN, Daliento L, Davenport A, Haapio M, Hillege H, House AA. Cardio-renal syndromes: report from the consensus conference of the Acute Dialysis Quality Initiative. Euro Heart J. 2010;31:703-711. doi:10.1093/eurheartj/ehp507
KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney International supplements. 2012 March;2:Issue 1. www.kidney-international.org
Du XJ, Bathgate RA, Samuel CS, Dart AM, Summers RJ. Cardiovascular effects of relaxin: from basic science to clinical therapy. Nat Rev Cardiol. 2010;7:48-58.